Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/551
Title: Preventing postoperative Crohn's disease with anti-TNFs: Almost there
Authors: Sorrentino, D.
Issue Date: 2012
Source: November 35, (11), 2012, p. 28-35
Pages: 28-35
Journal: Practical Gastroenterology
Abstract: Crohn's disease patients often suffer recurrence after surgery in a relatively short time. Hence, prevention of such complication is an important management consideration. Conventional medical therapies such as antibiotics, mesalamine, and thiopurines have shown little if any benefit for this indication. Recent promising data have shown that postoperative recurrence can be prevented in between 90 and 100% of patients when anti-tumor necrosis factor (TNF) are given immediately after surgery. Ongoing randomized clinical trials are now seeking to confirm these findings on a larger scale. This review will focus on the published studies that have used anti-TNFs to prevent postoperative recurrence, outline possible long-term strategies for these patients and review the potential implications of these data.
Resources: http://www.practicalgastro.com/pdf/November11/Sorrentino.pdfhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed10&AN=2012362745
Keywords: colonoscopyCrohn disease/dt [Drug Therapy];Crohn disease/su [Surgery];drug dose increase;drug dose reduction;drug efficacy;drug withdrawal;human;infusion related reaction/si [Side Effect];low drug dose;postoperative period;recurrent disease;review;adalimumab/ct [Clinical Trial];adalimumab/dt [Drug Therapy];azathioprine/ct [Clinical Trial];azathioprine/cm [Drug Comparison];azathioprine/dt [Drug Therapy];infliximab/ae [Adverse Drug Reaction];infliximab/ct [Clinical Trial];infliximab/cb [Drug Combination];infliximab/cm [Drug Comparison];infliximab/dt [Drug Therapy];mesalazine/ct [Clinical Trial];mesalazine/cm [Drug Comparison];mesalazine/dt [Drug Therapy];mesalazine/po [Oral Drug Administration];methotrexate/ct [Clinical Trial];methotrexate/cb [Drug Combination];methotrexate/cm [Drug Comparison];methotrexate/dt [Drug Therapy];methotrexate/po [Oral Drug Administration];placebo;tumor necrosis factor inhibitor/ct [Clinical Trial];tumor necrosis factor inhibitor/dt [Drug Therapy];tumor necrosis factor inhibitor/pd [Pharmacology]
Type: Article
Appears in Sites:Sunshine Coast HHS Publications

Show full item record

Page view(s)

68
checked on Mar 27, 2025

Google ScholarTM

Check


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.